Literature DB >> 34843930

Role of EZH2 in bone marrow mesenchymal stem cells and immune-cancer interactions.

Zhaoyun Liu1, Yue Jia2, Yixuan Guo3, Hao Wang4, Rong Fu5.   

Abstract

In recent years, methylation modification has been determined to be vital for the biological regulation of normal cells, tumor cells, and tumor microenvironment immune cells. Enhancer of zeste homology 2 (EZH2), a component of the Polycomb Repressive Complex 2 (PRC2), catalyzes the trimethylation of the downstream gene in the tri-methylates histone three lysine 27 (H3K27me3) position, which causes chromatin pyknosis, and thus, silences the expression of related genes. In this paper, we reviewed the role of EZH2 in regulating bone marrow mesenchymal stem cell differentiation and the immune cell function in tumor microenvironment, summarized all types of existing EZH2 inhibitors and the main clinical trials, and proposed relevant ideas for potential clinical applications.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  BMSC; EZH2; EZH2 inhibitor; Immunity; Multispectral differentiation

Mesh:

Substances:

Year:  2021        PMID: 34843930     DOI: 10.1016/j.critrevonc.2021.103547

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  1 in total

1.  Novel Quinoline Compounds as EZH2 Inhibitors for Treating Cancer.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-04-13       Impact factor: 4.632

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.